IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Welch & Forbes LLC

Welch & Forbes LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 169,319 shares of the company’s stock after acquiring an additional 82 shares during the quarter. Welch & Forbes LLC’s holdings in IDEXX Laboratories were worth $70,003,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Flossbach Von Storch SE lifted its position in IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after purchasing an additional 464,791 shares during the period. Assenagon Asset Management S.A. increased its holdings in IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $113,104,000. Vontobel Holding Ltd. increased its holdings in IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after buying an additional 198,404 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $71,893,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on IDXX shares. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Trading Down 1.9 %

Shares of IDXX opened at $429.03 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a 50 day simple moving average of $437.06 and a 200-day simple moving average of $450.19. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $574.94. The stock has a market cap of $34.89 billion, a price-to-earnings ratio of 40.21, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.